Form 4/A for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2022-05-10 00:00:00 ET · period of report 2022-01-03 · accession 0001213900-22-025289 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-05-10 | 2022-01-03 | ORMP | Mayer Arie | Dir | A - Grant | — | +6,000 | 6,000 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-03 | A | A | 6,000 | — | 6,000 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. (F2) This amendment is being filed to correct an administrative error in the Form 4 filed by Dr. Mayer, which reported that 9,000 shares of common stock were beneficially owned by him following the reported transaction. Dr. Mayer beneficially owned 6,000 shares of common stock following the reported transaction. |